---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-168521"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:57:38.641553+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics appoints Thomas R. Staab, II as CFO effective May 11, 2026

## Summary
- Staab, a 25-year healthcare finance veteran, most recently CFO of LENSAR (LNSR) until May 2026.
- Base salary of $428,000 with 45% target bonus; inducement equity of 10,000 RSUs and 450,000 option shares.
- Interim CFO Thomas McGauley resigns May 10, 2026 but will stay through filing of Q1 10-Q and provide consulting transition.
- Staab's RSUs vest 25% after 10 days, remainder quarterly; options vest 25% after 1 year then monthly over 3 years.

## SEC filing metadata
- accession: 0001193125-26-168521
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000119312526168521/0001193125-26-168521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000119312526168521/d81080d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-168521
- JSON: https://secwatch.observer/filing/0001193125-26-168521.json
- Plain text: https://secwatch.observer/filing/0001193125-26-168521.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.